Randomized Placebo Controlled Pilot Trial to determine the efficacy of an IL22 agonist (F-652) in patients with Alcoholic Hepatitis

Medicine & Life Sciences

1. interleukin-22 100%
2. Alcoholic Hepatitis 63%
3. Placebos 50%
4. Hepatitis 38%
5. Safety 27%
6. Random Allocation 17%
7. Survival 9%
8. Contraindications 8%
9. Inpatients 7%
10. Pharmacokinetics 6%
11. Steroids 6%
12. Research Personnel 6%
13. Randomized Controlled Trials 5%
14. Clinical Trials 5%
15. Morbidity 5%